Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 27 July 2017, 09:22 HKT/SGT
Share:
    

Source: Eisai
U.S. FDA Approves Additional Use of Antiepileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures

TOKYO, July 27, 2017 - (JCN Newswire) - Eisai Co., Ltd. has announced that on July 26, 2017 (U.S. time), its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) for Eisai's antiepileptic drug (AED) Fycompa (perampanel) as monotherapy use for the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older.

The FDA's regulatory pathway for monotherapy use(1), which was communicated in September 2016, states that "it is acceptable to extrapolate the efficacy and safety of drugs approved as adjunctive therapy for the treatment of partial-onset seizures to their use as monotherapy for the treatment of partial-onset seizures." Fycompa is the first AED to be approved as monotherapy for partial-onset seizures in accordance with this regulatory pathway.

Fycompa is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. It is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at postsynaptic AMPA receptors. It was originally approved in the United States as an adjunctive therapy for the treatment of partial-onset seizures (with or without secondarily generalized seizures) and primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. With the approval of monotherapy for partial-onset seizures, Fycompa can now be prescribed to all patients with partial-onset seizures 12 years of age and older in the United States.

Epilepsy affects approximately 2.9 million people in the United States. Epilepsy is broadly categorized by seizure type, with partial-onset seizures accounting for approximately 60% of epilepsy cases.(2) Eisai considers neurology a therapeutic area of focus, and through the provision of new treatment options such as Fycompa monotherapy for partial-onset seizures in the United States, seeks to further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

(1) FDA Communication. Reference ID: 3985169. September 13, 2016.
(2) Hauser WA, et al. Epilepsia, 34(3):453-468,1993

About Fycompa (perampanel)

Fycompa is a first-in-class AED discovered and developed by Eisai. With epileptic seizures being mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at postsynaptic AMPA receptors. Fycompa is available in tablet form to be taken once daily orally at bedtime. In addition, a new oral suspension formulation has been approved and is being marketed in the United States. Fycompa is currently approved in more than 55 countries and territories, including Japan, the United States, and in Europe as an adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older. In addition, Fycompa has been approved in more than 45 countries, including Japan, the United States, and in Europe as an adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. Based on the new additional use approval, Fycompa is now indicated in the United States for the treatment of partial-onset seizures (with or without secondarily generalized seizures) and the adjunctive treatment of PGTC in patients with epilepsy aged 12 and older. Fycompa is approved in Japan as an adjunctive therapy for partial-onset seizures (with or without secondarily generalized seizures) or PGTC seizures in patients with epilepsy showing inadequate response to other AEDs. Furthermore, Eisai is conducting respective global Phase III studies for the agent in pediatric patients with partial-onset seizures or PGTC seizures and in patients with seizures associated with Lennox-Gastaut syndrome. Additionally, a Phase III study as monotherapy for partial-onset seizures is being conducted in Japan.

For further information on Fycompa in the United States, including Important Safety Information, please visit the Fycompa product website (https://fycompa.com).

About Epilepsy Treatment

The goal of epilepsy treatment is to be seizure free. When diagnosed with epilepsy, patients undergo monotherapy treatment with antiepileptic drugs. In cases where the treatment's efficacy on seizure control is inadequate, the initial treatment can typically be replaced with a different monotherapy or combination therapy.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


July 27, 2017 09:22 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 11, 2018 15:32 HKT/SGT
Eisai: Oral Antifungal Agent Nailin Capsules 100mg to be Launched in Japan
July 10, 2018 10:14 HKT/SGT
Eisai: Oral Presentation on Phase II Clinical Study Results of BAN2401 to be Presented at Alzheimer's Association International Conference (AAIC) 2018
July 9, 2018 14:07 HKT/SGT
Eisai: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment "GOOFICE 5mg Tablet" Published in The Lancet Gastroenterology & Hepatology
July 6, 2018 09:31 HKT/SGT
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 At 18 Months
July 4, 2018 17:18 HKT/SGT
Eisai Listed for 17th Consecutive Year in FTSE4GOOD Index Series
July 2, 2018 15:36 HKT/SGT
Eisai to Give Oral Presentation on Results of Phase III Head-to-Head Clinical Study of Lemborexant in Insomnia Disorder
June 22, 2018 10:58 HKT/SGT
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN)
June 21, 2018 09:51 HKT/SGT
AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL
June 14, 2018 09:11 HKT/SGT
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research
June 13, 2018 11:53 HKT/SGT
Eisai to Establish New Research Facility "Eisai Center for Genetics Guided Dementia Discovery" in Cambridge, Massachusetts, USA
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: